Cellectis Reveals Preclinical Data On First Allogeneic Dual CAR T-Cell Product In Non-Hodgkin Lymphoma

Cellectis SA CLLS released preclinical data on its product candidate UCART20x22 at the American Association for Cancer Research (AACR) Annual Meeting.
The Company said that the data showed preclinical proof of concept with the potential to overcome common mechanisms of resistance to CAR T-cell therapies in relapsed or refractory Non-Hodgkin Lymphoma (r/r NHL), such as single-antigen escape or tumor heterogeneity.
UCART20x22 is Cellectis' first allogeneic dual CAR T-cell product candidate developed for patients with r/r NHL.
UCART20x22 showed strong activity against tumor cell lines expressing either a single antigen, CD20 or CD22, or both simultaneously.
In vivo preclinical models demonstrate that UCART20x22 efficiently eradicates tumors expressing both or either antigen, and sustained presence of UCART20x22 cells was observed in the bone marrow after tumor clearance.
In vitro assays against primary cells from Non-Hodgkin Lymphoma patients with diverse CD22 and CD20 antigen levels demonstrate that UCART20x22 has potent and specific cytotoxic activity.
An Investigational New Drug application (IND) for UCART20x22 is expected to be filed this year.
Price Action: CLLS shares are down 1.94% at $4.29 during the market session on the last check Monday.